NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 6, 2010, Pages 1817-1821

  Zheng, Jin ^a,b   Liu, Qiang ^b   Li, Yan ^c   Yang, Jiandong ^a   Ma, Ji ^a   Yu, Fang ^a   Shi, Hengjun ^b   Ren, Qinyou ^b   Zhang, Rui ^c   Zhang, Jin ^c   Xue, Yan ^a   Tao, Yurong ^a   Jiang, Ning ^a   Guo, Hang ^a   Yao, LiBo ^c   Liu, Wenchao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Department of Biochemistry and Molecular Biology ^*  (China)

Author keywords

Breast cancer; CD24; Metastatic potential; NDRG2

Indexed keywords

EID: 79956072095     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Aigner S, Ramos CL, Hafezi-Moghadam A, et al (1998). CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J, 12, 1241-51.
2. Aigner S, Sthoeger ZM, Fogel M, et al (1997). CD24, a mucintype glycoprotein, is a ligand for P-selectin on human tumor cells. Blood, 89, 3385-95.
3. Baumann P, Cremers N, Kroese F, et al (2005). CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res, 65, 10783-93.
4. Choi YL, Lee SH, Kwon GY, et al (2007). Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder. Arch Pathol Lab Med, 131, 275-81.
5. Deng Y, Yao L, Chau L, et al (2003). N-Myc downstreamregulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer, 106, 342-7.
6. Hu XL, Liu XP, Lin SX, et al (2004). NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol, 10, 3518-21.
7. Kim A, Kim MJ, Yang Y, et al (2009). Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis, 30, 927-36.
8. Kim JB, Ko E, Han W, et al (2008). CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer, 8, 118-27.
9. Kim YJ, Borsig L, Varki N M, et al (1998). P-selectin deficiency at tenuates tumor growth and metastasis. Proc Natl Acad Sci USA, 95, 9325-30.
10. Kristiansen G, Sammar M, Altevogt P (2004). Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol, 35, 255-62.
11. Kristiansen G, Winzer KJ, Mayordomo E, et al (2003). CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res, 9, 4906-13.
12. Lee DC, Kang YK, Kim WH, et al (2008). Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res, 68, 4210-20.
13. Lerebours F, Lidereau R (2002). Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol, 44, 121-41.
14. Li J, Xin PL, Shu XL, et al (2002). Expression pattern of ndr2 gene, a candidate tumor-suppressor, in different human tissues and tumors. Prog Biochem Biophys, 29, 223-7.
15. Lim SC (2005). CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother, 59, S351-4.
16. Lim SC, Oh SH (2005). The role of CD24 in various human epithelial neoplasias. Pathol Res Pract, 201, 479-86.
17. Liu N, Wang L, Liu X, et al (2007). Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun, 358, 164-9.
18. Liu N, Wang L, Li X, et al (2008). N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res, 36, 5335-49.
19. Lorentzen A, Vogel LK, Lewinsky RH, et al (2007). Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer, 7, 192-9.
20. Lusis EA, Watson MA, Chicoine MR, et al (2005). Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res, 65, 7121-6.
21. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumors. Nature, 406, 747-52.
22. Popescu NC, Zimonjic DB (2002). Chromosome and gene alterations in breast cancer as markers for diagnosis and prognosis as well as pathogenetic targets for therapy. Am J Med Genet, 115, 142-9.
23. Senner V, Sturm A, Baur I, et al (1999). CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol, 58, S795-802.
24. Shen L, Zhao ZY, Wang YZ, et al (2008). Immunohistochemical detection of Ndrg2 in the mouse nervous system. Neuroreport, 19, 927-31.
25. Shon SK, Kim A, Kim JY, et al (2009). Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun, 385, 198-203.
26. Wang L, Liu N, Yao L, et al (2008). NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells. Cell Physiol Biochem, 21, 239-50.
27. Zhao H, Zhang J, Lu J, et al (2008). Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer, 8, 303-11.